Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 02 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1834% % -23%
Return On Assets -35% % -51%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 68,401,349 shares 18%
Entity Public Float $1,757,900,000 USD 23%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 60,690,820 shares 10%
Weighted Average Number of Shares Outstanding, Diluted 60,690,820 shares 10%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $214,712,000 USD 28%
General and Administrative Expense $70,883,000 USD 45%
Operating Income (Loss) $285,595,000 USD -32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $255,565,000 USD -40%
Income Tax Expense (Benefit) $278,000 USD 1444%
Net Income (Loss) Attributable to Parent $255,843,000 USD -40%
Earnings Per Share, Basic -4.22 USD/shares -28%
Earnings Per Share, Diluted -4.22 USD/shares -28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $131,549,000 USD -7.2%
Marketable Securities, Current $598,643,000 USD 58%
Other Assets, Current $605,000 USD -65%
Assets, Current $741,358,000 USD 40%
Property, Plant and Equipment, Net $5,688,000 USD 190%
Operating Lease, Right-of-Use Asset $8,687,000 USD -24%
Other Assets, Noncurrent $8,671,000 USD 1641%
Assets $937,134,000 USD 24%
Accounts Payable, Current $1,221,000 USD 14%
Employee-related Liabilities, Current $3,658,000 USD 93%
Accrued Liabilities, Current $23,181,000 USD -4.4%
Liabilities, Current $27,906,000 USD -2.3%
Operating Lease, Liability, Noncurrent $5,345,000 USD -38%
Liabilities $33,251,000 USD -11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,080,000 USD 18%
Retained Earnings (Accumulated Deficit) $561,759,000 USD -84%
Liabilities and Equity $937,134,000 USD 24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $48,477,000 USD -53%
Net Cash Provided by (Used in) Financing Activities $450,520,000 USD
Net Cash Provided by (Used in) Investing Activities $12,982,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 69,038,943 shares 16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $34,873,000 USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $131,549,000 USD -7.4%
Deferred Tax Assets, Valuation Allowance $133,193,000 USD 75%
Deferred Tax Assets, Gross $135,218,000 USD 72%
Operating Lease, Liability $8,849,000 USD -25%
Depreciation $1,418,000 USD
Payments to Acquire Property, Plant, and Equipment $4,317,000 USD 1130%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $255,678,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid $9,692,000 USD -26%
Operating Lease, Liability, Current $3,504,000 USD 8.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,049,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,916,000 USD 0.18%
Operating Lease, Weighted Average Discount Rate, Percent 0.067 pure -4.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $843,000 USD -37%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,110,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $58,580,000 USD 264%
Unrecognized Tax Benefits $5,762,000 USD 60%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,617,000 USD -23%
Additional Paid in Capital $1,464,561,000 USD 43%
Share-based Payment Arrangement, Expense $46,277,000 USD 98%